Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics' stock price has been volatile, decreasing significantly over the past year. Key events include a stock plunge following an underwritten stock offering and the exit of the Principal Financial Officer in early February 2026. In late 2025, the FDA granted Fast Track status to a neuropathic pain asset and accepted a rolling submission request for a gene therapy. In November 2025, the company reported a revenue decrease due to a collaboration agreement with Genentech in 2024, while also recruiting patients for a neurology clinical study and presenting data from the STAAR study in Fabry disease. In October 2025, the FDA reiterated its agreement to use eGFR slope as an endpoint for accelerated approval in Fabry disease. In September 2025, Sangamo presented data from the STAAR study in Fabry disease. In August 2025, Sangamo's stock was upgraded to a Zacks Rank #2 (Buy).

The demand for Sangamo Therapeutics' products does not typically exhibit direct consumer-driven seasonality. The demand for specialized therapies is primarily driven by patient need and medical prescription, which are generally not seasonal. However, the broader biotechnology sector experiences cyclical market movements, with the summer months often challenging for biotech investors due to regulatory delays and a lack of major catalysts.

Sangamo Therapeutics operates in the Healthcare sector and Biotechnology industry, translating science into medicines addressing the underlying causes of diseases. Its major product candidates include ST-920 for Fabry disease, TX200 for kidney transplantation rejection prevention, and SB-525 for hemophilia A. The company also has preclinical programs focusing on tauopathies, ALS/FTD, and Huntington's disease.

Sangamo Therapeutics is headquartered in Brisbane, California, with research operations and manufacturing in the San Francisco Bay Area. It has strategic partnerships with global pharmaceutical and biotechnology firms to expand research and accelerate pipeline development.

Sangamo Therapeutics' brand reputation has been characterized by promising scientific advancements and financial challenges. Analyst consensus ratings are generally "Hold," with some "Buy" recommendations. Positive clinical developments, particularly with the gene therapy isa-vec for Fabry disease, contribute to a favorable safety profile. Financial concerns, including revenue declines and net losses, undermine internal funding capacity. Partnership setbacks, such as Pfizer passing on Sangamo's Hemophilia A asset, add uncertainty to its pipeline strategy.

Sangamo Therapeutics has 136 institutional owners and shareholders, holding a total of 63,950,226 shares. Major institutional owners include Vanguard Group Inc and Renaissance Technologies Llc. Institutional ownership accounts for approximately 18.7% of shares, individual insiders hold about 1.22%, public companies hold 0.966%, and the general public holds around 79.1%.